A dose-dependent response in efficacy was observed, with analysis of covariance showing a significant lowering of sitting SBP and DBP in the 2.5 and 5 mg/day CS-3150 groups compared with placebo (all p < 0.001). CS-3150 1.25 mg/day significantly lowered sitting SBP (p = 0.0412). Target BP achievement was also dose dependent. Similarly, 24-h BP changes showed a clear dose relationship, and all CS-3150 doses significantly lowered 24-h BP compared with placebo (1.25 mg/day: p = 0.0038 and 0.0154 for 24-h SBP and DBP, respectively; 2.5 and 5 mg/day: all p < 0.0001). Compared with placebo, all CS-3150 doses were well tolerated. Hyperkalemia (>=5.5 mEq/L) was briefly detected in the 2.5 and 5 mg/day groups, but it was transient and recovered without treatment.
